FORT LEE, N.J., Oct. 1 /PRNewswire-FirstCall/ — Neurologix,
Inc. (OTC Bulletin Board:
NRGX), today announced that new details of the company’s
landmark, randomized, double-blind Phase 2 clinical trial of
NLX-P101, its investigational gene therapy for advanced Parkinson’s
disease (PD), were presented during a symposium at the 2nd World
Parkinson Congress in Glasgow, Scotland. Co-principal
investigator of the trial, Dr. Peter Lewitt, Director of the
Parkinson’s Disease and Movement Disorders program at Henry Ford
Hospital, reported that, in addition to statistically significant
improvements over the entire blinded study period in the
off-medication motor scores between the treated and sham groups on
the Unified Parkinson’s Disease Rating Scale (UPDRS) Part 3 (Motor
section), 75 percent of patients in the treatment group were
considered to have had a meaningful response to NLX-P101 (i.e., a
five point or greater reduction in the off-medication UPDRS motor
scores), which is comparable to the response rate of 71 percent in
a recent study of Deep Brain Stimulation (Weaver FM, Follett K,
Stern M, et al. Bilateral deep brain stimulation vs. best medical
therapy for patients with advanced Parkinson’s disease: a
randomized controlled trial. JAMA 2009; 301:63-73).
Dr. Lewitt also emphasized that results showed a positive safety
profile for NLX-P101, with no serious adverse events related to the
gene therapy or surgical procedure reported. Although details
regarding the study methodology were also provided, such as
catheter placement in the subthalamic nucleus (STN), specific
quantitative outcomes were not discussed during the presentation,
as these will be presented in a peer-reviewed publication,
currently under review.
Earlier this year, Neurologix disclosed top-line results for
this Phase 2 trial, announcing that study participants who received
NLX-P101 ex
‘/>”/>
SOURCE
